Condition: Autosomal Dominant Hypocalcemia Type 1 (ADH1) · Sponsor: Calcilytix Therapeutics, Inc., a BridgeBio company
The overall objective of this study is to evaluate the pharmacokinetics (PK), efficacy, and safety of encaleret in pediatric participants from birth to 17 years of age with ADH1.
This description comes directly from the study's public registry record.
Medical Information · 650-600-3610 · MedInfo@bridgebio.com
Always discuss trial participation with your own doctor first.
| Yale University | New Haven, Connecticut, United States | Recruiting |
| Children's National Medical Center | Washington D.C., District of Columbia, United States | Recruiting |
| Nemours Children's Health | Jacksonville, Florida, United States | Recruiting |
| The Children's Hospital of Philadelphia | Philadelphia, Pennsylvania, United States | Recruiting |
| Royal London Hospital | London, United Kingdom | Recruiting |
| Royal Manchester Children's Hospital | Manchester, United Kingdom | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07080385